

20 May 2026

Use of Biologic Medicines in Secondary Care

I would be grateful if you could respond with the number of patients treated with specific medicines between the start of January 2026 and the end of March 2026, or the latest three-month period for which data is available. Please include data for all hospitals in your organisation.

1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of Jan 2026 and end of Mar 2026?

Name of medicine	Number of patients treated
1.1 Benralizumab (Fasenra)	N/A
1.2 Depemokimab (Exdensur)	N/A
1.3 Dupilumab (Dupixent)	277
1.4 Lebrikizumab (Ebglyss)	14
1.5 Mepolizumab (Nucala)	N/A
1.6 Omalizumab (Xolair)	36
1.7 Reslizumab (Cinqaero)	N/A
1.8 Tezepelumab (Tezspire)	N/A

20 May 2026

Name of medicine	Number patients treated
1.1 Benralizumab (Fasenra)	8
1.2 Depemokimab (Exdensur)	0
1.3 Dupilumab (Dupixent)	<5
1.4 Lebrikizumab (Ebglyss)	0
1.5 Mepolizumab (Nucala)	12
1.6 Omalizumab (Xolair)	0
1.7 Reslizumab (Cinqaero)	0
1.8 Tezepelumab (Tezspire)	26

Use of <5 (less than five): We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act - Personal Information relating to a third party, as the small numbers involved could make patients personally identifiable.

Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.

20 May 2026

2. How many patients were treated for severe asthma, COPD, CRwNP with the following medicines in the 3 months between the start of Jan 2026 and end of Mar 2026?

Name of medicine	Severe asthma (please include all types or references to asthma)	Chronic Obstructive Pulmonary Disease (COPD)	Chronic Rhinosinusitis with Nasal Polyps (CRwNP)
2.1 Benralizumab (Fasenra)	142	<10	Information not held
2.2 Depemokimab (Exdensur)	0	0	“ “
2.3 Dupilumab (Dupixent)	70	0	“ “
2.4 Mepolizumab (Nucala)	320	11	“ “
2.5 Omalizumab (Xolair)	22	<5	“ “
2.6 Reslizumab (Cinqaero)	<5	0	“ “
2.7 Tezepelumab (Tezspire)	155	<5	“ “

Again, we are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act - Personal Information relating to a third party.

3. How many patients were treated for Atopic Dermatitis with the following medicines in the 3 months between the start of Jan 2026 and end of Mar 2026?

Name of medicine	Number of patients with Atopic Dermatitis
3.1 Dupilumab (Dupixent)	272
3.2 Lebrikizumab (Ebglyss)	14

20 May 2026

4. How many patients were treated by department in total, regardless of diagnosis, with the following medicines in the 3 months between the start of Jan 2026 and end of Mar 2026?

Respiratory & Dermatology response:

Name of medicine	Respiratory Departments	Dermatology Departments	Other Departments
4.1 Benralizumab (Fasenra)	142	N/A	
4.2 Depemokimab (Exdensur)	0	N/A	
4.3 Dupilumab (Dupixent)	70	277	
4.4 Lebrikizumab (Ebglyss)	320	14	
4.5 Mepolizumab (Nucala)	22	N/A	
4.6 Omalizumab (Xolair)	<5	36	
4.7 Reslizumab (Cinqaero)	155	N/A	
4.8 Tezepelumab (Tezspire)	142	N/A	